Eyenovia said on Friday it will discontinue a late-stage study for its experimental drug-device combination to treat near-sightedness and cut about 50% of its workforce.

Presbyopia is an age-related refractive condition marked by a gradual decline in near vision, typically emerging between ages ...

It happens when a parasite that can be found in water invades the eye, damaging the cornea, causing severe pain and ...

Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...

In June 2024, a canalicular gel device (Lacrifill, Nordic Pharma) was introduced to the US market, and a recent study has ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...

Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...

The recent approval of Vuity by the Food and Drug Administration marks a significant advancement in treating presbyopia, a common age-related condition that causes blurry vision. Local ...

DelveInsight's Dry Eye Disease Treatment Market Insights report provides the current and forecast market analysis, individual ...